Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Drugs for Pulmonary/Respiratory Diseases in Phase II Clinical Development in UNITED KINGDOM

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Verona Pharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BE PHARMA 2020

              Participation Not Confirmed

              Update your events

              Verona Pharma to Present Phase 2b data with Ensifentrine in COPD at the European Respiratory Society International Congress 2020

              Contact the Supplier

              Lead Product(s): Ensifentrine,Tiotropium Bromide

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RPL554

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 24, 2020

              Details:

              Subgroup analysis of Phase 2b data will be provided by Verona Pharma showing that nebulized ensifentrin as monotherapy or applied to tiotropium enhances lung function in moderate to serious COPD patients regardless of smoking status or chronic bronchitis history over 4 weeks.

              Verona Pharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BE PHARMA 2020

              Participation Not Confirmed

              Update your events

              Verona Pharma Initiates Multiple Dose Part of Phase 2 Clinical Trial with pMDI Formulation of Ensifentrine in COPD

              Contact the Supplier

              Lead Product(s): Ensifentrine

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RPL554

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 19, 2020

              Details:

              Company has initiated second, multiple dose, part of a Phase 2 trial to evaluate the pressurized metered-dose inhaler formulation of ensifentrine in patients with moderate to severe chronic obstructive pulmonary disease.

              Verona Pharma

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BE PHARMA 2020

              Participation Not Confirmed

              Update your events

              Verona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription

              Contact the Supplier

              Lead Product(s): Ensifentrine

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: RA Capital Management

              Deal Size: $183.0 million Upfront Cash: Undisclosed

              Deal Type: Private Placement July 17, 2020

              Details:

              Verona Pharma intends to use the net proceeds from the Financing primarily to fund its Phase 3 clinical program ENHANCE in chronic obstructive pulmonary disease and for general corporate purposes. The Phase 3 clinical trials are planned to start later in 2020.

              Verona Pharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BE PHARMA 2020

              Participation Not Confirmed

              Update your events

              Verona Pharma Shares FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program

              Contact the Supplier

              Lead Product(s): Ensifentrine

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 14, 2020

              Details:

              The FDA’s comments follow its review of the End-of-Phase 2 briefing package that included data from 16 clinical trials involving over 1,300 subjects as well as supportive nonclinical and product development data.

              Verona Pharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BE PHARMA 2020

              Participation Not Confirmed

              Update your events

              Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment

              Contact the Supplier

              Lead Product(s): Ensifentrine

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 01, 2020

              Details:

              Analysis supports ensifentrine’s efficacy in COPD as monotherapy and on top of standard of care treatment in patients who remain symptomatic.

              Verona Pharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BE PHARMA 2020

              Participation Not Confirmed

              Update your events

              Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD

              Contact the Supplier

              Lead Product(s): Ensifentrine

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 31, 2020

              Details:

              Results from the single dose part of the study demonstrated a statistically significant and clinically meaningful increase in lung function as measured by forced expiratory volume in one second.

              Verona Pharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BE PHARMA 2020

              Participation Not Confirmed

              Update your events

              Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research

              Contact the Supplier

              Lead Product(s): Ensifentrine

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 14, 2020

              Details:

              Paper demonstrates ensifentrine’s potential in improving lung function and quality of life symptoms

              Verona Pharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BE PHARMA 2020

              Participation Not Confirmed

              Update your events

              Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy

              Contact the Supplier

              Lead Product(s): Ensifentrine

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 13, 2020

              Details:

              Primary endpoint met at all doses: ensifentrine produced clinically and statistically significant dose-dependent improvements in lung function.

              Verona Pharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BE PHARMA 2020

              Participation Not Confirmed

              Update your events

              Verona Pharma to Report 4 Week Phase 2b COPD Dose-ranging Study Results with Nebulized Ensifentrine on Top of Tiotropium Therapy

              Contact the Supplier

              Lead Product(s): Ensifentrine

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 10, 2020

              Details:

              Phase 2b dose-ranging study is evaluating nebulized ensifentrine as an add-on to treatment with a long acting bronchodilator in patients with moderate-to-severe COPD.

              PharmaCompass__DigitalAd